{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Munoz-Martinez S"],"funding":["Cancer Research UK","Instituto de Salud Carlos III","European Association for the Study of the Liver","Wellcome Trust"],"pagination":["1891-1901"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9347559"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["42(8)"],"pubmed_abstract":["<h4>Background & aims</h4>Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.<h4>Methods</h4>Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.<h4>Results</h4>Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage a"],"journal":["Liver international : official journal of the International Association for the Study of the Liver"],"pubmed_title":["Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study."],"pmcid":["PMC9347559"],"funding_grant_id":["PS3416","CD18/00126","C9380/A18084","C9380/A26813","PI15/00145","FI19/00222","RCCPDB‐Nov21/100008","C18342/A23390","PI19/00819","16‐0026","PI18/0358","PI044031","PI18/00768","PI18/00542","PI13/01229"],"pubmed_authors":["Tawheed A","Watson R","Varela M","Rios J","Hollande C","Vergara M","Mello V","Sapena V","Lachenmayer A","Villani R","Bandi JC","Rodriguez-Lope C","Bruix J","Guarino M","Gonzalez Santiago JM","Blaise L","Acevedo J","Alves RCP","da Fonseca L","Carrilho FJ","Nault JC","Leal CRG","Peck-Radosavljevic M","Rojas A","Alvares-da-Silva MR","Reig M","Vilgrain V","Alqahtani SA","Iavarone M","Pascual S","Ferguson Theodoro C","Elvevi A","Anders M","Tacke F","Viera-Alves DE","Franca A","Reeves HL","Mocan T","Munoz-Martinez S","Sanduzzi-Zamparelli M","Braconi C","Bouattour M","Lozano M","Forner A","El-Kassas M","Garcia-Juarez I","Cabibbo G","Sparchez Z","Moctezuma-Velazquez C","Pinero F","Perello C","Pinato DJ","D'Alessio A","Sala M","Rimassa L"],"additional_accession":[]},"is_claimable":false,"name":"Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.","description":"<h4>Background & aims</h4>Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population.<h4>Methods</h4>Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.<h4>Results</h4>Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage a","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-19T05:58:55.163Z","creation":"2024-11-09T16:12:40.075Z"},"accession":"S-EPMC9347559","cross_references":{"pubmed":["35608939"],"doi":["10.1111/liv.15320"]}}